Clinical Trials

30 enrolled

Phase NA Active not recruiting

Triple Negative Breast Neoplasms

NCT01928589 2026-03-06

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

81 enrolled

Breast Neoplasms

NCT04703244 2026-03-03

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Recruiting

999 enrolled

Breast Neoplasms

NCT05710328 2026-03-02

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

235 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT07342283 2026-03-02

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT06627712 2026-01-30

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Phase 3 Recruiting

318 enrolled

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07378306 2026-01-30

FACT-TN

80 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07372079 2026-01-28

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

40 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT06596018 2025-12-30

Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy

Phase 1/2 Recruiting

96 enrolled

Breast Neoplasms

NCT06195709 2025-12-18

ECLECTIC

Phase 3 Recruiting

300 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00929214 2025-12-17

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

35 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

120 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03676257 2025-12-10

Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases

20,033 enrolled 9 charts

Breast Neoplasms

NCT04943497 2025-12-09

PROSPERITY

2,424 enrolled

Breast Neoplasms

NCT05076682 2025-12-03

Renaissance

80 enrolled

Triple Negative Breast Neoplasms

NCT06731140 2025-11-17

Resilire

10 enrolled

HER2 Negative Breast Cancer

NCT03283384 2025-09-19

NEOLBC

100 enrolled

BreastGastrointestinalLymphoidPlasma cell

Breast Neoplasms

NCT07152938 2025-09-15

AVR-CHEMO

Phase NA Completed

150 enrolled

Agnosia, Anxiety Disorders, Breast Neoplasms, Colonic Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms

NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Phase 1/2 Not yet recruiting

12 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07137793 2025-08-22

PTX / BC

46 enrolled

Breast Neoplasms

NCT07127315 2025-08-17

Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy

100 enrolled

Breast Neoplasms

NCT07108309 2025-08-07

AREAL

124 enrolled

Triple Negative Breast Neoplasms

NCT07104266 2025-08-05

Triple Negative Breast Cancer and Celecoxib. Pilot Study

30 enrolled

Triple Negative Breast Neoplasms

NCT06027541 2025-08-03

Young Patients With Early Breast Cancer

Active not recruiting

1,000 enrolled

Phase 2 Not yet recruiting

Breast Cancer Female

NCT07101614 2025-08-03

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

125 enrolled

Phase NA Active not recruiting

Triple Negative Breast Neoplasms

NCT02276443 2025-08-01

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

798 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07096180 2025-07-31

Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer

Recruiting

200 enrolled

Breast Neoplasms

NCT05300958 2025-07-22

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Phase 2 Terminated

25 enrolled

Triple Negative Breast Neoplasms

NCT06533722 2025-06-10

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

Phase 2 Completed

10 enrolled

HER2-negative Metastatic Breast Cancer

NCT06678048 2025-06-06

Arsenous Acid for Refractory Triple-Negative Breast Cancer

12 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07005557 2025-06-05

SENIOR

1,244 enrolled

Breast Neoplasms

NCT06990347 2025-05-25

A Study on the Efficacy and Safety of IPyC for HER2+ MBC

301 enrolled